

# Standardised report for MR: Follow-up of NEN

## Indication

Location of the primary tumor (if known):

Tumor-predisposition syndrome:

If yes:

Histology:

Type:

Differentiation:

Grade:

Clinical symptoms:

If yes, please describe:

Treatment:

Type (including watch and wait):

Date of start of last treatment:

Date of NADIR:

## Technique

Magnet:

Gadolinium-based contrast agent injection:

Name: Quantity: mL

Type of sequences: *(select all that apply)*

T2 fat saturated

T2 without fat saturation

In/Opposed-Phase imaging

4 set of DixonT1W

Dynamic T1 fat saturated:

DWI

MRCP

DCE-MR

Lower abdomen (if imaged):

T2 fat saturated:

T2 without fat saturation:

Dynamic T1 fat saturated:

### Qualitative assessment

Description of tumor burden: anatomical location and number of lesions: primary tumor (if present) and metastatic lesions:

% of liver involvement:

Changes in tumor phenotype:

Decrease of vascularisation:

Presence of necrosis:

### Quantitative assessment (according RECIST 1.1)

#### Size assessment according to RECIST 1.1 Criteria

Target lesions:

Target 1:                      Location:                      Size:                      mm

Target 2:                      Location:                      Size                      mm

Target 3:                      Location:                      Size                      mm

Target 4:                      Location:                      Size                      mm

Target 5:                      Location:                      Size                      mm

Sum size:                      % of change:

Target lesion response:

Non target lesions (location, evaluation - CR, PD, non PD non CR):

New lesions (description with anatomical location):

Overall response (CR, PR, SD, PD):

#### Viable tumor assessment according to mRECIST (applicable for TACE treatment)

Target 1:                      Location:                      Size:                      mm

Target 2:                      Location:                      Size:                      mm

Target 3:                      Location:                      Size:                      mm

Target 4:                      Location:                      Size:                      mm

Target 5:                      Location:                      Size:                      mm

Sum size:                      % of change:

mRECIST response:

#### Tumor necrosis assessment using intra-tumor ADC measurement (applicable for research)

Target 1:                      Location:                      ADC mean/min ( $10^{-3}$  mm<sup>2</sup>/s):

Target 2:                      Location:                      ADC mean/min ( $10^{-3}$  mm<sup>2</sup>/s):

Target 3:                      Location:                      ADC mean/min ( $10^{-3}$  mm<sup>2</sup>/s):

Target 4:                      Location:                      ADC mean/min ( $10^{-3}$  mm<sup>2</sup>/s):

Target 5:                      Location:                      ADC mean/min ( $10^{-3}$  mm<sup>2</sup>/s):

Sum of all ADC means/min:                      % of ADC mean/min change:

## Other relevant findings

Free text:

## Conclusions

Free text: